Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis

The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH). Due to the underlying chronic liver disease, patients with NASH often require different approaches to the assessment and management of suspected drug‐induced liver injury (DILI) compared to patients with healthy livers. However, currently no regulatory guidelines or position papers systematically address best practices pertaining to DILI in NASH clinical trials.

• Publication year

  2019

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2019-02-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.15153PMID 30761572PMCID 6593464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Initiative

  2020influential reference
• Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis

  2019cited by this paper
• A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

  2018cited by this paper
• NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018influential reference
• Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection

  2017influential reference
• Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

  2017cited by this paper
• The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

  2017cited by this paper
• Drug-induced Liver Injury: The Hepatic Pathologist's Approach.

  2017influential reference
• Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.

  2017cited by this paper
• American Liver Guidelines and Cutoffs for "Normal" ALT: A Potential for Overdiagnosis.

  2017cited by this paper
• Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.

  2017cited by this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV

  2017cited by this paper
• Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study

  2017cited by this paper
• Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cited by this paper
• Acute-on-chronic liver failure in cirrhosis

  2016cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

  2016cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

  2016cited by this paper
• Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.

  2016cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

  2015cited by this paper
• Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

  2015cited by this paper
• Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.

  2015cited by this paper
• Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

  2015cited by this paper
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

  2015influential reference
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015influential reference
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

  2015influential reference
• Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug‐Induced Liver Injury Network (DILIN)

  2015cited by this paper
• Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials

  2014influential reference
• Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

  2014cited by this paper
• A population-based study on the prevalence of NASH using scores validated against liver histology.

  2014influential reference
• Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease.

  2014cited by this paper
• Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)

  2014cited by this paper
• Causality Assessment for Suspected DILI During Clinical Phases of Drug Development

  2014influential reference
• Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

  2014cited by this paper
• Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

  2014cited by this paper
• World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

  2014cited by this paper
• An assessment by the Statin Liver Safety Task Force: 2014 update.

  2014cited by this paper
• Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

  2014cited by this paper
• Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

  2014cited by this paper
• Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations

  2013influential reference
• Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

  2013cited by this paper
• Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

  2013influential reference
• Diabetes type II, other medical conditions and pancreatic cancer risk: a prospective study in The Netherlands

  2013cited by this paper
• Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis

  2013cited by this paper
• Drug-induced steatohepatitis.

  2013cited by this paper
• Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

  2013cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis

  2012cited by this paper
• Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

  2012cited by this paper
• A pre-marketing ALT signal predicts post-marketing liver safety.

  2012cited by this paper
• &ggr;-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome

  2012cited by this paper
• Acute-on chronic liver failure.

  2012cited by this paper
• Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

  2011influential reference
• Endpoints and clinical trial design for nonalcoholic steatohepatitis

  2011influential reference
• Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

  2011influential reference
• A maxed-out liver: a case of acute-on-chronic liver failure.

  2011cited by this paper
• Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network

  2011cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

  2010cited by this paper
• Risk factors for idiosyncratic drug-induced liver injury.

  2010influential reference
• HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.

  2010cited by this paper
• Variability in the upper limit of normal for serum alanine aminotransferase levels: A statewide study

  2009cited by this paper
• NASH and cryptogenic cirrhosis: a histological analysis.

  2009cited by this paper
• Using controlled clinical trials to learn more about acute drug‐induced liver injury

  2008influential reference
• Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial

  2007cited by this paper
• A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver disease

  2007cited by this paper
• Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

  2007cited by this paper
• Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.

  2007cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006influential reference
• Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase

  2006cited by this paper
• Hy's law: predicting serious hepatotoxicity

  2006cited by this paper
• Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease

  2006cited by this paper
• Future use of the Glasgow alcoholic hepatitis score.

  2006cited by this paper
• Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Outcome and prognostic markers in severe drug‐induced liver disease

  2005cited by this paper
• Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes

  2005cited by this paper
• Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes

  2005cited by this paper
• Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

  2004cited by this paper
• Are patients with elevated liver tests at increased risk of drug-induced liver injury?

  2004cited by this paper
• Statins and Liver Toxicity: A Meta‐Analysis

  2004influential reference
• Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

  2003cited by this paper
• Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project

  2002influential reference
• Alanine Aminotransferase Levels: What's Normal?

  2002cited by this paper
• The rational use of potentially hepatotoxic medications in patients with underlying liver disease

  2002cited by this paper
• Nonalcoholic steatohepatitis.

  2001cited by this paper
• Progressive Liver Functional Impairment Is Associated with an Increase in AST/ALT Ratio

  1999cited by this paper
• Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

  1998cited by this paper
• Gallstones and diabetes: A case‐control study in a free‐living population sample

  1997cited by this paper
• From industry

  1991influential reference
• Gallstone formation during weight-reduction dieting.

  1989cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Double-Blind Randomized Placebo-Controlled Trial of Orlistat or the Treatment of Nonalcoholic Fatty Liver Disease

  year unknowncited by this paper

• Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

  2025cites this paper
• Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era

  2025cites this paper
• AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children.

  2025cites this paper
• Assessment of liver injury potential of investigational medicines in drug development.

  2025cites this paper
• Mitochondrial dysfunction in drug-induced hepatic steatosis: recent findings and current concept.

  2025cites this paper
• Drug-induced hepatotoxicity among critically ill patients in the intensive care unit

  2025cites this paper
• Computational design, synthesis, in vitro and in vivo evaluation of a 3,4-methylenedioxyphenol (sesamol) derivative as an NRF2/HO-1 pathway activator for protection against drug-induced liver injury

  2025cites this paper
• Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients

  2024cites this paper
• Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to noncirrhotic Advanced Fibrosis.

  2024cites this paper
• Drug-induced liver injury in patients with underlying liver disease.

  2024cites this paper
• What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?

  2024cites this paper
• Incretin-based investigational therapies for the treatment of MASLD/MASH.

  2024cites this paper
• Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests

  2024influential citation
• Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review

  2023cites this paper
• Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum

  2023cites this paper
• Challenges and opportunities in NASH drug development

  2023cites this paper
• Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study

  2023cites this paper
• Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  2023cites this paper
• Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review

  2022cites this paper
• Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease

  2022cites this paper
• Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

  2022cites this paper
• Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury

  2022cites this paper
• Mitochondrial alterations in fatty liver diseases.

  2022cites this paper
• ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.

  2021cites this paper
• Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials

  2021cites this paper
• Pharmacology of NASH

  2021cites this paper
• ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET].

  2021influential citation
• Blinding in Clinical Trials for Chronic Liver Diseases

  2021cites this paper
• Drug-Induced Liver Injury (DILI): Current status and future directions for drug development and the post-market setting

  2020cites this paper
• NRF-2 and nonalcoholic fatty liver disease.

  2020cites this paper
• Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring

  2020cites this paper
• Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence

  2020cites this paper
• Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

  2020cites this paper
• Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.

  2020cites this paper
• The regulatory state of nonalcoholic steatohepatitis and metabolism

  2020cites this paper
• Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

  2020influential citation
• Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations

  2020cites this paper
• Defining Appropriate Utilization of AST Testing.

  2020cites this paper
• Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis

  2019cites this paper
• Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors

  2019cites this paper